Company intelligence / Profile preview

Hybridize Therapeutics

Leiden, South Holland, Netherlandshybridizetherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Hybridize Therapeutics has developed a pipeline of RNA-based therapies targeting acute and chronic kidney diseases, with its lead program focused on direct antiviral therapy against BK Virus. The company entered a worldwide license agreement with AiCuris for this program, potentially worth up to €100M. Other programs are at earlier stages and target monogenic and inflammatory/fibrotic renal disorders. No published late-stage clinical results as of the latest available information.

Therapeutic areas: NephrologyInfectious Diseases
Modalities: RNA-based therapeutics (oligonucleotides)
Industry: Biotech

Drug pipeline

1 asset

HYB_JCV

Preclinical

Partnerships

AiCuris Anti-infective Cures AG (worldwide license agreement for BKV program)

Beyond the preview

Go deeper on Hybridize Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hybridize Therapeutics.